Until recently, the management
of breast cancer with chemotherapeutic agents has led to modest benefits. Hence, there is an urgent need
to introduce new active agents into the management of this disease. The
demonstration of a superior tumor response rate, time to disease progression,
and overall survival with the combination of capecitabine (Xeloda) and docetaxel
(Taxotere) compared with single-agent docetaxel in anthracycline-pretreated
patients indicates the important role of capecitabine in the treatment of
advanced breast cancer.
The use of this agent in combination therapy in breast cancer patients,
however, has only begun to be explored, as the agent has a unique mode of action
and can be combined safely with a variety of agents. Potential for
improvement in the therapeutic index of treatment with capecitabine-containing
combinations is suggested by (1) activity of other treatments (eg, taxanes,
cyclophosphamide [Cytoxan, Neosar], irinotecan [Camptosar], and vinorelbine [Navelbine],
as well as radiation therapy) in increasing tumor levels of thymidine
phosphorylase, the activating enzyme for capecitabine; (2) early-phase studies
showing activity of combinations with a variety of different agents; and (3)
preclinical data indicating potential for synergistic effects with a number of
In North America, cyclophosphamide/doxorubicin combinations at full
conventional dosages have been the basis of breast adjuvant treatment.[5-7]
Based upon the enhanced response rates of phase III trials in the neoadjuvant
setting (National Surgical Adjuvant Breast and Bowel Project trial B-27) and in
the adjuvant setting (the Aberdeen trial), cyclophosphamide/doxorubicin followed
by docetaxel may offer a new standard approach in the management of
early-disease patients.[8-10] As capecitabine/taxane combinations demonstrate a
higher response rate and better survival than docetaxel alone in metastatic
disease, the combination is being advanced into treatment of earlier disease.
The current US Oncology Adjuvant Trial (XEL242) addresses the question of
whether or not the use of capecitabine/docetaxel following classical
cyclophosphamide/doxorubicin (Adriamycin) (AC) offers any benefit over
single-agent docetaxel following AC. Additional similar studies are in
Weekly taxanes may offer a therapeutic advantage over traditional
every-3-week schedules of administration and are being actively studied.
Because of the ease of administration of taxanes on a weekly schedule and the
possibility of repetitively up-regulating thymidine phosphorylase, additional
studies are exploring the feasibility of weekly taxane treatment in combination
Preliminary findings using this approach in 19 anthracycline-pretreated
patients with metastatic breast cancer demonstrated activity with acceptable
toxicity in an ongoing phase I/II study. The recommended dose was identified
as intermittent oral capecitabine at 900 mg/m² twice daily on a 14-day schedule
every 3 weeks plus weekly docetaxel at 30 mg/m². There was a low incidence of
severe myelosuppression, with only one grade 4 event (neutropenia) being
observed; the most common grade 3 toxicity was palmar-plantar erythrodysesthesia
(in 3 of 19 patients). Objective tumor response was observed in two patients,
with seven patients demonstrating stable disease.
Meza et al have reported findings in a phase II study of paclitaxel at 175
mg/m² every 3 weeks, plus capecitabine at 825 mg/m² twice daily on days 1 to
14, as first- or second-line treatment of metastatic breast cancer. The
patients had a median age of 52 years (range: 35-76 years) and a median Karnofsky
performance status of 90. Among 47 evaluable patients, 34 patients received
this therapy as first-line treatment, and 13 patients as second-line treatment.
Of these patients, 13% (five patients with first-line treatment, and one with
second-line treatment) achieved a complete response; 30% of patients achieved
a partial response; and 38% had stable disease. Because of the small number
of patients, there is some variation in the partial responses in patients receiving
first- or second-line treatment (Figure
1). Overall, median time to disease progression was 44 weeks.
1. Polychemotherapy for early breast cancer: An overview of the randomized
trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet
2. O’Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with
capecitabine plus docetaxel combination therapy in anthracycline-pretreated
patients with advanced breast cancer: Phase III trial results. J Clin Oncol
3. O’Shaughnessy J: Clinical experience of capecitabine in metastatic
breast cancer. Eur J Cancer 38(suppl 2):10-14, 2002.
4. Budman D: Capecitabine. Invest New Drugs 18:355-363, 2000.
5. Abrams JS: Adjuvant therapy for breast cancerResults from the USA
consensus conference. Breast Cancer 8:298-304, 2001.
6. Abrams JS: North American adjuvant breast cancer trials. Recent results.
Cancer Res 152:417-428, 1998.
7. Budman D, Berry D, Cirrincione C, et al: Dose and dose intensity as
determinants of outcome in the adjuvant treatment of breast cancer. The Cancer
and Leukemia Group B. J Natl Cancer Inst 90:1205-1211, 1998.
8. Mamounas EP: NSABP protocol B-27. Preoperative doxorubicin plus
cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology
9. Valero V: Primary chemotherapy with docetaxel for the management of breast
cancer. Oncology 16(suppl 6)35-43, 2002.
10. Nabholtz JM, Tonkin K, Smylie M, et al: Chemotherapy of breast cancer:
Are the taxanes going to change the natural history of breast cancer? Expert
Opin Pharmacother 1:187-206, 2000.
11. Zimatore M, Danova M, Vassallo E, et al: Weekly taxanes in metastatic
breast cancer. Oncol Rep 9:1047-1052, 2002.
12. Scarfe A, Bodnar D, Tonkin K, et al: Interim results of a phase II study
of weekly docetaxel (Taxotere) combined with intermittant capecitabine (Xeloda)
for patients with anthracycline pretreated breast cancer (abstract 1984). Proc
Am Soc Clin Oncol 21:43b, 2002.
13. Meza L, Amin B, Hill T, et al: Capecitabine plus paclitaxel as first-or
second-line therapy: A multicenter phase II study in metastatic breast cancer.
Breast Cancer Res Treat 69:358a, 2001.
14. Budman DR: Vinorelbine (Navelbine): A third-generation vinca alkaloid.
Cancer Invest 15:475-490, 1997.
15. Nole F, Catania C, Mandala M, et al: Phase I study of vinorelbine and
capecitabine in advanced breast cancer (abstract). Breast Cancer Res Treat
16. Hess D, Thuerlimann B, Pagani O, et al: Phase I-II trial of capecitabine
and vinorelbine in elderly patients (pts > 65 y) with metastatic breast
cancer: SAKK 25/99 for the Swiss Group of Clinical Cancer Research (abstract
2915). Proc Am Soc Clin Oncol 21:274b, 2002.
17. Ahn J-H, Kim S-B, Lee J-S, et al: Phase II study of a combination
chemotherapy of capecitabine and vinorelbine in metastatic breast cancer with
previous exposure to anthracycline and taxane: Preliminary results (abstract
2030). Proc Am Soc Clin Oncol 21:55b, 2002.
18. Bunnell CA, Winer EP: Oral 5-FU analogues in the treatment of breast
cancer. Oncology 12(suppl 7):39-43, 1998.
19. Chan S-C, Wong L-N, Chow L: A phase II study on an all-oral regimen of
capecitabine (Xeloda), idarubicin, and cyclophosphamide (XIC) for metastatic
breast cancerSafety, efficacy and quality of life (abstract 2023). Proc Am
Soc Clin Oncol 21:53b, 2002.
20. Leyland-Jones B: Trastuzumab: Hopes and realities. Lancet Oncol
21. Hortobagyi GN: Overview of treatment results with trastuzumab (Herceptin)
in metastatic breast cancer. Semin Oncol 28:43-47, 2001.
22. Shawver LK, Slamon D, Ullrich A: Smart drugs: Tyrosine kinase inhibitors
in cancer therapy. Cancer Cell 1:117-123, 2002.
23. Budman D, Calkabro A: Synergistic combinations of EGFR tyrosine kinase
inhibitors and conventional chemotherapy: In vitro median effect analysis in
cell lines (abstract 521). Breast Cancer Res Treat (in press).
24. Chou TC, Motzer RJ, Tong Y, et al: Computerized quantitation of synergism
and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma
cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst
25. Kurokawa H, Arteaga CL: Inhibition of erbB receptor (HER) tyrosine
kinases as a strategy to abrogate antiestrogen resistance in human breast
cancer. Clin Cancer Res 7:4436s-4442s, 2001.
26. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y: Antitumor activity of
combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines
capecitabine/5'-dFUrd in human breast cancer models. Cancer Chemother Pharmacol
27. Perez E, Hillman D, Mailliard J, et al: Randomized phase II study of 2
schedules of irinotecan (CPT-11) for patients with refractory metastatic breast
cancer: An NCCTG Cooperative Group study (abstract 206). Proc Am Soc Clin Oncol
28. Cao S, Hapke G, Rustum Y: Enhanced antitumor activity of Xeloda by
irinotecan in nude mice bearing human A253 and FaDu head and neck xenografts
(abstract 464). Proc Am Assoc Cancer Res 42, 2001.
29. Hirawat S, Kolitz J, Lichtman S, et al: Sequential irinotecan and
capecitabine (Xeloda) given every other week in the management of advanced
metastatic carcinoma: A phase I study (abstract 2127). Proc Am Soc Clin Oncol
30. Budman DR, Calabro A: In vitro search for synergy and antagonism:
Evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer
Res Treat 74:41-46, 2002.
31. Rosso R, Del Mastro L, Durando A, et al: Capecitabine in association with
epirubicin and docetaxel as a first line treatment in advanced breast cancer. A
multicenter phase II study (abstract 353). Breast Can Res Treat 69:270, 2001.
32. Fujimoto-Ouchi K, Tanaka Y, Tominaga T: Schedule dependency of antitumor
activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and
docetaxel in breast cancer models. Clin Cancer Res 7:1079-1086, 2001.
33. Budman D, Calabro A, Kreis W: In vitro evaluation of synergism or
antagonism with combinations of new cytotoxic agents. Anticancer Drugs